Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints
AA Levesque, EA Kohn, E Bresnick, A Eastman - Oncogene, 2005 - nature.com
The topoisomerase I inhibitor SN38 arrests cell cycle progression primarily in S or G 2
phases of the cell cycle in a p53-independent manner. The Chk1 inhibitor, 7 …
phases of the cell cycle in a p53-independent manner. The Chk1 inhibitor, 7 …
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
R Li, PD Sutphin, D Schwartz, D Matas, N Almog… - Oncogene, 1998 - nature.com
Loss of normal p53 function was found frequently to interfere with response of cancer cells to
conventional anticancer therapies. Since more than half of all human cancers possess p53 …
conventional anticancer therapies. Since more than half of all human cancers possess p53 …
Partial p53 reactivation is sufficient to induce cancer regression
B Klimovich, L Meyer, N Merle, M Neumann… - Journal of Experimental …, 2022 - Springer
Background Impaired p53 function is one of the central molecular features of a tumor cell
and even a partial reduction in p53 activity can increase the cancer risk in mice and men …
and even a partial reduction in p53 activity can increase the cancer risk in mice and men …
Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents
M Michaelis, F Rothweiler, B Agha, S Barth… - Cell death & …, 2012 - nature.com
Adaptation of wild-type p53 expressing UKF-NB-3 cancer cells to the murine double minute
2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency (13/20) and multi-drug …
2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency (13/20) and multi-drug …
New developments in small molecules targeting p53 pathways in anticancer therapy
The tumor suppressor p53 is frequently inactivated in a wide variety of cancers and point
mutations or deletions of the p53 gene are associated with poor prognosis in cancer. About …
mutations or deletions of the p53 gene are associated with poor prognosis in cancer. About …
Improving cancer therapy through p53 management
S Haupt, Y Haupt - Cell Cycle, 2004 - Taylor & Francis
The tumor suppressor p53 normally acts to appropriately co-ordinate cellular responses to
stress stimuli. When p53 activity is disabled, the onset of malignancy is a potential …
stress stimuli. When p53 activity is disabled, the onset of malignancy is a potential …
[HTML][HTML] New insights into p53 based therapy
A common step in human cancer is the inactivation of the p53 tumor suppressor pathway.
This occurs either by mutations in the coding region of the p53 gene itself, or equally …
This occurs either by mutations in the coding region of the p53 gene itself, or equally …
Awakening the “guardian of genome”: reactivation of mutant p53
The role of tumor suppressor protein p53 is undeniable in the suppression of cancer upon
oncogenic stress. It induces diverse conditions such as cell-cycle arrest, cell death, and …
oncogenic stress. It induces diverse conditions such as cell-cycle arrest, cell death, and …
P53: a determinant of the cell cycle response to DNA damage
MB Kastan - Novel Approaches to Selective Treatments of Human …, 1993 - Springer
Historically, most efficacious chemotherapuetic regimens have been developed empirically
(ie by trial and error) rather than by a rational understanding of the differences between …
(ie by trial and error) rather than by a rational understanding of the differences between …
Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy
G Bossi, A Sacchi - Head & neck, 2007 - Wiley Online Library
Background. In the majority of human cancers, the tumor suppressor activity of p53 is
impaired because of mutational events or interactions with other proteins (ie, MDM2). The …
impaired because of mutational events or interactions with other proteins (ie, MDM2). The …